ID

17232

Descripción

Effect of Androgen Blockade Therapy on Thymus Function in Older Patients Who Have Undergone Radical Prostatectomy for Localized Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00379119

Link

https://clinicaltrials.gov/show/NCT00379119

Palabras clave

Versiones (1)
  1. 1/9/16 1/9/16 -
Subido en

1 de septiembre de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Prostate Cancer NCT00379119

Inglés

Eligibility Prostate Cancer NCT00379119

1 formularios  
Criteria
Descripción

Criteria

histologically confirmed adenocarcinoma of the prostate
Descripción

adenocarcinoma of the prostate

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0007112
underwent prior radical prostatectomy as local definitive therapy for prostate cancer
Descripción

Radical prostatectomy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0194810
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI-1
C1512693
has received ≥ 9 months of androgen blockade therapy (either single-agent luteinizing hormone-releasing hormone or combined androgen blockade) for serologic progression after surgery
Descripción

androgen blockade therapy (either single-agent luteinizing hormone-releasing hormone or combined androgen blockade)

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1518041
UMLS CUI [2]
C3495882
serologic progression defined as a rising prostate-specific antigen, which has risen serially on two determinations (from baseline) ≥ 1 week apart, and no objective evidence of metastatic disease
Descripción

rising prostate-specific antigen; no objective evidence of metastatic disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201544
UMLS CUI [2]
C0027627
prior radiotherapy for serologic progression allowed
Descripción

Radiotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1522449
did not receive any form of androgen blockade therapy within the past 9 months
Descripción

androgen blockade therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0279492
no metastatic disease by abdominal/pelvic ct scan and whole-body scan
Descripción

no metastatic disease by abdominal/pelvic ct scan and whole-body scan

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0027627
UMLS CUI [1,2]
C0203669
UMLS CUI [2,1]
C0027627
UMLS CUI [2,2]
C1641132
Inclusion Criteria: Patient Characteristics
Descripción

Inclusion Criteria: Patient Characteristics

Alias
UMLS CUI-1
C0815172
able to tolerate ct scanning in the supine position
Descripción

CT scan

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0040405
no prior medical condition known to have effects on the thymus, including myasthenia gravis, lymphoma, hyperthyroidism, or cachexia
Descripción

medical condition affecting the thymus, including myasthenia gravis, lymphoma, hyperthyroidism, or cachexia

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0040113
UMLS CUI [2]
C0026896
UMLS CUI [3]
C0024299
UMLS CUI [4]
C0020550
UMLS CUI [5]
C0006625
no autoimmune disorders
Descripción

autoimmune disorders

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0004364
no acute illness, including active infection requiring antibiotics
Descripción

no acute illness, including active infection

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001314
UMLS CUI [2]
C0009450
prior concurrent therapy: see disease characteristics
Descripción

concurrent therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0009429
no prior systemic chemotherapy
Descripción

systemic chemotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1883256
no prior immunological therapy
Descripción

immunological therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021083
no prior single-agent antiandrogen (e.g., high-dose bicalutamide)
Descripción

antiandrogen

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0002842
no prior or concurrent 5-alpha reductase inhibitors (e.g., finasteride), pc-spes, or estrogen-containing nutraceuticals
Descripción

5-alpha reductase inhibitors, pc-spes, or estrogen-containing nutraceuticals

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2936788
UMLS CUI [2]
C0756934
UMLS CUI [3]
C0014939
no concurrent systemic steroid therapy (topical steroids allowed)
Descripción

systemic steroids

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2825233
Volver a la parte superior de la página

Similar models

Eligibility Prostate Cancer NCT00379119

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
adenocarcinoma of the prostate
Item
histologically confirmed adenocarcinoma of the prostate
boolean
C0007112 (UMLS CUI [1])
Radical prostatectomy
Item
underwent prior radical prostatectomy as local definitive therapy for prostate cancer
boolean
C0194810 (UMLS CUI [1])
Item Group
Inclusion Criteria
C1512693 (UMLS CUI-1)
androgen blockade therapy (either single-agent luteinizing hormone-releasing hormone or combined androgen blockade)
Item
has received ≥ 9 months of androgen blockade therapy (either single-agent luteinizing hormone-releasing hormone or combined androgen blockade) for serologic progression after surgery
boolean
C1518041 (UMLS CUI [1])
C3495882 (UMLS CUI [2])
rising prostate-specific antigen; no objective evidence of metastatic disease
Item
serologic progression defined as a rising prostate-specific antigen, which has risen serially on two determinations (from baseline) ≥ 1 week apart, and no objective evidence of metastatic disease
boolean
C0201544 (UMLS CUI [1])
C0027627 (UMLS CUI [2])
Radiotherapy
Item
prior radiotherapy for serologic progression allowed
boolean
C1522449 (UMLS CUI [1])
androgen blockade therapy
Item
did not receive any form of androgen blockade therapy within the past 9 months
boolean
C0279492 (UMLS CUI [1])
no metastatic disease by abdominal/pelvic ct scan and whole-body scan
Item
no metastatic disease by abdominal/pelvic ct scan and whole-body scan
boolean
C0027627 (UMLS CUI [1,1])
C0203669 (UMLS CUI [1,2])
C0027627 (UMLS CUI [2,1])
C1641132 (UMLS CUI [2,2])
Item Group
Inclusion Criteria: Patient Characteristics
C0815172 (UMLS CUI-1)
CT scan
Item
able to tolerate ct scanning in the supine position
boolean
C0040405 (UMLS CUI [1])
medical condition affecting the thymus, including myasthenia gravis, lymphoma, hyperthyroidism, or cachexia
Item
no prior medical condition known to have effects on the thymus, including myasthenia gravis, lymphoma, hyperthyroidism, or cachexia
boolean
C0012634 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0040113 (UMLS CUI [1,3])
C0026896 (UMLS CUI [2])
C0024299 (UMLS CUI [3])
C0020550 (UMLS CUI [4])
C0006625 (UMLS CUI [5])
autoimmune disorders
Item
no autoimmune disorders
boolean
C0004364 (UMLS CUI [1])
no acute illness, including active infection
Item
no acute illness, including active infection requiring antibiotics
boolean
C0001314 (UMLS CUI [1])
C0009450 (UMLS CUI [2])
concurrent therapy
Item
prior concurrent therapy: see disease characteristics
boolean
C0009429 (UMLS CUI [1])
systemic chemotherapy
Item
no prior systemic chemotherapy
boolean
C1883256 (UMLS CUI [1])
immunological therapy
Item
no prior immunological therapy
boolean
C0021083 (UMLS CUI [1])
antiandrogen
Item
no prior single-agent antiandrogen (e.g., high-dose bicalutamide)
boolean
C0002842 (UMLS CUI [1])
5-alpha reductase inhibitors, pc-spes, or estrogen-containing nutraceuticals
Item
no prior or concurrent 5-alpha reductase inhibitors (e.g., finasteride), pc-spes, or estrogen-containing nutraceuticals
boolean
C2936788 (UMLS CUI [1])
C0756934 (UMLS CUI [2])
C0014939 (UMLS CUI [3])
systemic steroids
Item
no concurrent systemic steroid therapy (topical steroids allowed)
boolean
C2825233 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial